Welcome to our dedicated page for Immunocore Holdings plc American Depositary Shares news (Ticker: IMCR), a resource for investors and traders seeking the latest updates and insights on Immunocore Holdings plc American Depositary Shares stock.
Immunocore Holdings plc (NASDAQ: IMCR) is a leading biotechnology company at the forefront of developing groundbreaking T cell receptor (TCR) bispecific immunotherapies. Leveraging its world-class TCR technology, Immunocore aims to harness the body's immune system to target and destroy diseased cells. The company's proprietary platform, known as ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer), is designed to treat a variety of serious conditions, including cancer, infectious diseases, and autoimmune disorders.
Based in the United Kingdom, Immunocore has a significant presence in the United States, where the majority of its revenue is generated. The company's most notable product, KIMMTRAK® (tebentafusp-tebn), is the first approved TCR therapy for metastatic uveal melanoma, available in the United States, European Union, Canada, Australia, and the United Kingdom.
In recent news, Immunocore has entered into a clinical trial collaboration with Bristol Myers Squibb to investigate IMC-F106C, an ImmTAC bispecific TCR candidate, in combination with nivolumab for treating advanced cutaneous melanoma. This Phase 3 trial aims to assess the efficacy and safety of this combination therapy.
Immunocore's robust pipeline includes several clinical-stage programs in oncology and infectious diseases. Notable developments include ongoing trials for IMC-I109V for Hepatitis B Virus (HBV) and advanced pre-clinical programs in autoimmune diseases. Additionally, the company is expanding its PRAME ImmTAC franchise with two new candidates, IMC-P115C and IMC-T119C, targeting solid tumors.
Financially, Immunocore has successfully transitioned from a research-focused organization to a revenue-generating entity. The company's collaborative efforts with partners like DELFI Diagnostics aim to enhance cancer therapy monitoring through innovative liquid biopsy assays.
Immunocore continues to pioneer in the field of immunotherapy, with a mission to deliver transformative treatments that radically improve patient outcomes.
The FAK inhibitors market is set for significant growth from 2019 to 2032, driven by emerging therapies with enhanced safety profiles and novel delivery methods for various cancers. Key companies, including Verastem, GlaxoSmithKline, Merck, and Immunocore (IMCR), are actively developing FAK inhibitors. Notable therapies under development include VS-6766 + defactinib and KIMMTRAK (tebentafusp), with several others awaiting approval. However, market expansion may be restricted by factors like therapy failures, high pricing, and access challenges. The report emphasizes the increasing focus on molecular therapies as traditional cytotoxic treatments have not yet cured cancer, highlighting the importance of FAK inhibitors for future oncology treatments.
Engimmune Therapeutics has announced a leadership transition as Dr. Søren Mouritsen steps down as CEO, with Dr. Lars Nieba appointed as his successor. This transition is part of a planned strategy to advance the company's T-cell receptor (TCR)-based therapeutics development. Dr. Nieba brings over 25 years of experience in biopharmaceuticals, including leadership roles at Roche and Bayer, which positions him well to enhance Engimmune's strategic direction. Under Dr. Mouritsen's leadership, the company was established and successfully completed seed financing. Board Chairman Bent Jakobsen and other leaders expressed confidence in Nieba's ability to navigate the next stages of development, leveraging Engimmune's innovative technologies. Engimmune focuses on TCR therapies aimed at treating cancer and autoimmune diseases, utilizing advanced methodologies such as genome editing and machine learning.
Immunocore Holdings plc (Nasdaq: IMCR) presented new data on KIMMTRAK (tebentafusp-tebn) at the 2023 American Association for Cancer Research Annual Meeting. The Phase 3 trial indicated that early reductions in circulating tumor DNA (ctDNA) correlate with improved overall survival (OS). With 46 months of median follow-up from the Phase 2 trial, the median OS was confirmed at 16.8 months, significantly higher than historical rates in metastatic uveal melanoma (mUM). Additionally, ctDNA reduction by week 9 was noted in 88% of first-line patients, and those achieving ctDNA clearance saw an 84% one-year OS. Immunocore plans to release further OS data from the Phase 3 trial later in 2023.
Grey Wolf Therapeutics presented new preclinical data at the AACR Annual Meeting 2023 demonstrating the potential of their first-in-class ERAP1 inhibitors to generate and upregulate cancer antigens, enhancing the efficacy of MHC Class I directed therapies. Collaborating with Immunocore (NASDAQ: IMCR), the study highlighted the upregulation of the ACTL8 cancer peptide, leading to improved killing of cancer cell lines by the ImmTAC therapy. The CEO, Peter Joyce, emphasized the potential of their candidate GRWD5769 in clinical trials and the unique approach of targeting ERAP inhibition to mobilize T cell responses against tumors. This research could pave the way for novel therapeutic targets and immuno-oncology strategies, enhancing anti-tumor responses in various cancers.
The BRAF mutant metastatic melanoma market is poised for growth driven by enhanced diagnostic methods and increased healthcare spending globally. According to DelveInsight's report, the market is projected to expand significantly from 2019 to 2032, with a focus on the 7MM regions including the US and several EU countries. BRAF mutations are prevalent in approximately 50% of melanoma cases, with the V600E mutation being the most common. Leading companies such as Merck Sharp & Dohme and AstraZeneca are developing novel therapies, and the pipeline includes over 15 emerging treatments currently in mid-phase trials. While the market outlook is optimistic, challenges include therapy discontinuations and high treatment costs.
Immunocore Holdings Plc (Nasdaq: IMCR) announced its participation in the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 3:45 p.m. EDT. The conference will feature a live webcast of their presentation, accessible through the 'Investors' section of Immunocore's website. A replay will be available afterward for a limited time.
Immunocore specializes in developing innovative T cell receptor (TCR) bispecific immunotherapies to address various diseases, including cancer and autoimmune conditions. Their lead product, KIMMTRAK, has received regulatory approval for treating HLA-A*02:01-positive adult patients with advanced uveal melanoma in multiple regions including the U.S. and EU.
Immunocore Holdings plc (Nasdaq: IMCR) will present four posters at the AACR Annual Meeting 2023 from April 14-18, focusing on its innovative therapy, tebentafusp-tebn. Significant data includes three-year overall survival updates for metastatic uveal melanoma and findings that early ctDNA reduction correlates with improved survival.
The presentations will be led by authors Ryan Sullivan, Esra Güç, Joe Sacco, and Marcus Butler across various sessions. Immunocore's KIMMTRAK, a T cell receptor immunotherapy, is already approved in several regions for treating advanced uveal melanoma.
Immunocore reported financial results for Q4 and the full year 2022, with KIMMTRAK generating net revenues of £42 million ($51 million) in Q4 and £117 million ($141 million) for the year. The therapy is approved in over 30 countries and has treated nearly 200 patients under an early access program. The company has a cash position of £401.6 million, providing a runway into 2026. R&D expenses rose to £89.2 million as the company advances various clinical trials, including new targets for PRAME and PIWIL1. Notable awards were received for KIMMTRAK, reflecting its clinical benefits.
Immunocore Holdings Plc (Nasdaq: IMCR) announces upcoming presentations at key investor conferences in March 2023, focusing on its pioneering T cell receptor (TCR) bispecific immunotherapies. The conferences include:
- Cowen 43rd Annual Health Care Conference on March 6 at 1:30 p.m. ET
- Oppenheimer 33rd Annual Healthcare Conference on March 14 at 8:00 a.m. ET
- Barclays Global Healthcare Conference on March 15 at 3:35 p.m. ET
- Jefferies Biotech on the Bay Summit on March 16, 2023
Live webcasts of the presentations will be available on Immunocore's website.
FAQ
What is the current stock price of Immunocore Holdings plc American Depositary Shares (IMCR)?
What is the market cap of Immunocore Holdings plc American Depositary Shares (IMCR)?
What does Immunocore Holdings plc do?
What is the proprietary platform of Immunocore?
What is KIMMTRAK?
Where does Immunocore generate most of its revenue?
What recent collaboration has Immunocore entered into?
What are some of the clinical-stage programs Immunocore is working on?
What are PRAME ImmTAC candidates?
What is the mission of Immunocore?
How has Immunocore evolved financially?
What role does DELFI Diagnostics play in Immunocore's research?
